PL3842431T3 - Związek [1,2,4]triazolo[1,5-a]pirydyny jako inhibitor jak i jego zastosowanie - Google Patents
Związek [1,2,4]triazolo[1,5-a]pirydyny jako inhibitor jak i jego zastosowanieInfo
- Publication number
- PL3842431T3 PL3842431T3 PL19852944.8T PL19852944T PL3842431T3 PL 3842431 T3 PL3842431 T3 PL 3842431T3 PL 19852944 T PL19852944 T PL 19852944T PL 3842431 T3 PL3842431 T3 PL 3842431T3
- Authority
- PL
- Poland
- Prior art keywords
- triazolo
- application
- pyridine compound
- jak inhibitor
- jak
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- -1 [1,2,4]triazolo[1,5-a]pyridine compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810968207 | 2018-08-23 | ||
| PCT/CN2019/102209 WO2020038457A1 (zh) | 2018-08-23 | 2019-08-23 | 作为JAK抑制剂的[1，2，4]三唑并[1，5-a]吡啶类化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3842431T3 true PL3842431T3 (pl) | 2024-05-20 |
Family
ID=69592871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19852944.8T PL3842431T3 (pl) | 2018-08-23 | 2019-08-23 | Związek [1,2,4]triazolo[1,5-a]pirydyny jako inhibitor jak i jego zastosowanie |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11919896B2 (pl) |
| EP (1) | EP3842431B1 (pl) |
| JP (1) | JP7140920B2 (pl) |
| KR (1) | KR102603729B1 (pl) |
| CN (1) | CN112739696B (pl) |
| AU (1) | AU2019326647B2 (pl) |
| CA (1) | CA3106490C (pl) |
| ES (1) | ES2973331T3 (pl) |
| HR (1) | HRP20240300T1 (pl) |
| HU (1) | HUE065919T2 (pl) |
| PL (1) | PL3842431T3 (pl) |
| RS (1) | RS65243B1 (pl) |
| WO (1) | WO2020038457A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12419873B2 (en) * | 2020-02-13 | 2025-09-23 | Zhuhai United Laboratories Co., Ltd. | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases |
| AU2021222686B2 (en) * | 2020-02-21 | 2023-06-29 | Zhuhai United Laboratories Co., Ltd. | Crystalline form of JAK inhibitor and application thereof |
| WO2022161205A1 (zh) | 2021-01-29 | 2022-08-04 | 珠海联邦制药股份有限公司 | 一种含有jak抑制剂或其盐或其晶型的口服制剂及其制备方法和应用 |
| CA3229388A1 (en) | 2021-08-19 | 2023-02-23 | Zhuhai United Laboratories Co., Ltd. | Local topical preparation containing jak inhibitor, salts or crystal forms thereof, and preparation method and use thereof |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CN117924272A (zh) * | 2022-10-26 | 2024-04-26 | 珠海联邦制药股份有限公司 | 一种jak抑制剂类药物中间体的合成方法及其应用 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220688A1 (en) | 2005-07-27 | 2009-09-03 | Buddy Tools, Llc | Drywall tape and joint compound dispenser |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010187A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2018019223A1 (zh) * | 2016-07-26 | 2018-02-01 | 张文燕 | 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 |
| CA2939286A1 (en) | 2016-08-17 | 2018-02-17 | Pharmascience Inc. | Spirocyclic containing compounds and pharmaceutical uses thereof |
| CN108341814B (zh) * | 2017-01-23 | 2021-09-03 | 上海翔锦生物科技有限公司 | Jak激酶抑制剂及其应用 |
| EP3668993A4 (en) * | 2017-08-14 | 2021-05-12 | Camp4 Therapeutics Corporation | HEPATIC DISEASE TREATMENT METHODS |
-
2019
- 2019-08-23 PL PL19852944.8T patent/PL3842431T3/pl unknown
- 2019-08-23 RS RS20240239A patent/RS65243B1/sr unknown
- 2019-08-23 AU AU2019326647A patent/AU2019326647B2/en active Active
- 2019-08-23 US US17/263,416 patent/US11919896B2/en active Active
- 2019-08-23 JP JP2021534418A patent/JP7140920B2/ja active Active
- 2019-08-23 EP EP19852944.8A patent/EP3842431B1/en active Active
- 2019-08-23 HR HRP20240300TT patent/HRP20240300T1/hr unknown
- 2019-08-23 HU HUE19852944A patent/HUE065919T2/hu unknown
- 2019-08-23 ES ES19852944T patent/ES2973331T3/es active Active
- 2019-08-23 CN CN201980041955.2A patent/CN112739696B/zh active Active
- 2019-08-23 KR KR1020217008505A patent/KR102603729B1/ko active Active
- 2019-08-23 CA CA3106490A patent/CA3106490C/en active Active
- 2019-08-23 WO PCT/CN2019/102209 patent/WO2020038457A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3106490C (en) | 2023-03-07 |
| US20210155621A1 (en) | 2021-05-27 |
| WO2020038457A1 (zh) | 2020-02-27 |
| AU2019326647B2 (en) | 2022-02-10 |
| JP2021534259A (ja) | 2021-12-09 |
| ES2973331T3 (es) | 2024-06-19 |
| EP3842431C0 (en) | 2023-12-27 |
| AU2019326647A1 (en) | 2021-02-18 |
| CA3106490A1 (en) | 2020-02-27 |
| KR102603729B1 (ko) | 2023-11-17 |
| EP3842431A1 (en) | 2021-06-30 |
| CN112739696B (zh) | 2022-08-02 |
| HRP20240300T1 (hr) | 2024-05-24 |
| CN112739696A (zh) | 2021-04-30 |
| EP3842431B1 (en) | 2023-12-27 |
| EP3842431A4 (en) | 2022-06-01 |
| JP7140920B2 (ja) | 2022-09-21 |
| RS65243B1 (sr) | 2024-03-29 |
| KR20210049858A (ko) | 2021-05-06 |
| US11919896B2 (en) | 2024-03-05 |
| HUE065919T2 (hu) | 2024-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE065919T2 (hu) | [1,2,4]triazolo[1,5-A]piridin vegyület mint JAK-gátló és annak alkalmazása | |
| SG11202101148UA (en) | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | |
| IL260923B (en) | History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors | |
| EP3107914B8 (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
| ZA201902562B (en) | Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides | |
| EP4074710A4 (en) | PYRAZOLO[1,5-A]PYRIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | |
| EP3268000A4 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| ZA201802842B (en) | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| EP3837250A4 (en) | Pyrazine compounds and uses thereof | |
| IL290419A (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| IL280211A (en) | History of triazoloquinoxaline with additional transformations | |
| IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors | |
| EP3508487A4 (en) | PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND | |
| SG11202100108SA (en) | Tie-coat composition | |
| HK40048902A (en) | Triazolo-pyrimidine compounds and uses thereof | |
| HK40041290A (en) | Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors | |
| ZA202101658B (en) | Triazolo-pyrimidine compounds and uses thereof | |
| EP3903788A4 (en) | PYRAZOLO[1,5-A] PYRIMIDINE MACROCYCLIC COMPOUND | |
| TWI925811B (zh) | 吡化合物及其用途 | |
| HK40021321A (en) | Processes for making triazolo[4,5d]pyramidine derivatives and intermediates thereof | |
| HK40031593A (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| HK40036179A (en) | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof | |
| AU2019903724A0 (en) | Antiviral Compounds and their use | |
| HK40032545A (en) | PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS |